Inozyme Pharma Files 2025 Proxy Statement
| Field | Detail |
|---|---|
| Company | Inozyme Pharma, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, sec-filing
TL;DR
Inozyme Pharma dropped its 2025 proxy statement, shareholders vote soon.
AI Summary
Inozyme Pharma, Inc. filed its definitive proxy statement on April 29, 2025, for the fiscal year ending December 31, 2024. The filing, designated as DEF 14A, outlines the company's governance and shareholder matters. The company is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing provides shareholders with crucial information regarding company operations, executive compensation, and voting matters, enabling informed participation in corporate decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information.
Key Players & Entities
- Inozyme Pharma, Inc. (company) — Registrant
- 0000950170-25-060198 (filing_id) — Accession Number
- 20250429 (date) — Filing Date
- 321 SUMMER STREET SUITE 400 BOSTON MA 02210 (address) — Company Headquarters
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used by companies to solicit proxies from shareholders for their annual or special meetings. It provides detailed information about matters to be voted on, such as director elections, executive compensation, and other corporate actions.
When was this specific proxy statement filed?
This definitive proxy statement was filed on April 29, 2025.
What is the fiscal year end for Inozyme Pharma, Inc. as indicated in the filing?
The fiscal year end for Inozyme Pharma, Inc. is December 31.
Where is Inozyme Pharma, Inc. headquartered?
Inozyme Pharma, Inc. is headquartered at 321 Summer Street, Suite 400, Boston, MA 02210.
What is the SEC file number for Inozyme Pharma, Inc.?
The SEC file number for Inozyme Pharma, Inc. is 001-39397.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 29, 2025 regarding Inozyme Pharma, Inc..